CS-2701
CS-2701 性质
| 沸点 | 626.2±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.48±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO:67.0(最大浓度 mg/mL);199.19(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 8.17±0.30(Predicted) |
CS-2701 用途与合成方法
E7820 (ER68203-00) inhibits both bFGF- and VEGF-driven ube formation of human umbilical vascular endothelial cell (HUVEC) in a dose-dependent manner with IC
50
of 0.20 and 0.24 μg/ml, respectively.
E7820 inhibits proliferation of HUVEC induced by either bFGF or VEGF in serum-free medium (SFM). The IC
50
values are 0.10 and 0.081 μg/ml, respectively. Antiproliferative activity of E7820 against both WiDr and LoVo cells is very weak compared with that against HUVEC. The values of IC50 were 29 and 15 μg/ml, respectively.
E7820 (ER68203-00) (50-200 mg/kg; p.o. ; twice daily for 14 days) delays the growth of WiDr cells inoculated s.c..
E7820 (200-400 mg/kg; p.o.;once daily for 4 days) potently inhibits WiDr-induced angiogenesis.
| Animal Model: | Six-week-old female nude mice (KSN mice, WiDr-induced angiogenesis model) |
| Dosage: | 50, 100, 200 mg/kg |
| Administration: | p.o. ; twice daily for 14 days from 2 days after inoculation of the tumor cells |
| Result: | The antitumor effect was dose-dependent at 50, 100, and 200 mg/kg, and the tumor growth rates were 52%, 46%, and 27%, respectively. |
CS-2701 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-14571 | 1 mg | 431 | ||
| 2024-01-25 | HY-14571 | CS-2701 | 289483-69-8 | 5mg | 950 |
